FDA approval announcements for new ANDA filings and biosimilar candidates - particularly high-value products with limited competition
Biosimilar launch progress and market share capture for Fylnetra (Neulasta biosimilar) and pipeline products
Generic drug pricing trends - particularly for core hospital injectable portfolio where pricing erosion or stabilization impacts margins
Manufacturing capacity expansion updates and facility inspection outcomes (FDA Form 483s or warning letters)
low - Pharmaceutical demand is relatively inelastic as products address critical medical needs regardless of economic conditions. Hospital utilization may fluctuate modestly with elective procedures during recessions, but emergency and critical care drugs (core portfolio) maintain stable demand. Respiratory products see seasonal patterns but limited GDP sensitivity.
Rising interest rates have moderate negative impact through higher financing costs for working capital (long inventory cycles for sterile manufacturing) and potential M&A activity. However, with debt/equity of 0.85 and strong cash generation (13% FCF yield), balance sheet impact is manageable. Valuation multiples may compress as investors rotate from growth stocks, though low current valuation (7.9x EV/EBITDA) provides cushion.
Ongoing generic drug pricing pressure from consolidation among pharmacy benefit managers and hospital GPOs, with average annual price erosion of 5-15% on mature products requiring constant new product launches to maintain revenue growth
Regulatory risk from FDA manufacturing inspections and potential consent decrees, particularly given international manufacturing footprint in China where supply chain scrutiny has intensified
Biosimilar market adoption uncertainty as payers and providers navigate interchangeability regulations and physician acceptance remains variable compared to reference biologics
value - The stock trades at attractive valuation multiples (7.9x EV/EBITDA, 1.8x P/S) relative to specialty pharma peers, with strong cash generation (13% FCF yield) appealing to value investors seeking undervalued healthcare exposure. Modest growth profile (13.6% revenue growth, 16% net income growth) and limited dividend yield suggest this is not a pure growth or income play, but rather a value opportunity with potential re-rating catalysts from biosimilar success.
No analyst coverage available for this stock.
2 signals unavailable — limited data for this stock
Trend
-15.5% vs SMA 50 · -7.6% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
INSTITUTIONAL OWNERSHIP
AMPH News
Unable to load news
About
amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int